CSL Behring’s Swiss research sits at sitem-insel, the institute for translational and entrepreneurial medicine. The company develops biologics for rare and serious disease — immunology, haematology, respiratory, transplant — and sells in more than a hundred countries. The BioAlps twentieth-year series asked it to speak as a neighbour, not as a logo.
A long partnership, not a grant drive
The Research Acceleration Initiative is CSL’s name for sitting with universities, hospitals, and institutes early, with funding and with its own scientists in the room. In Switzerland that table has been extended to CHUV and the University of Geneva. The company is a long member of BioAlps and has kept a partnership with Biopôle.
Their own sentence, kept from a partner: many companies have a grant drive; the way you talk to us is different. We file it beside our desk rule. A material is not purchased. It is read with the people who will have to live with the reading.